Биологическая терапия среднетяжелых и тяжелых форм атопического дерматита в детском возрасте

Атопический дерматит (АтД) — заболевание, характеризующееся хроническим воспалением, дисфункцией эпидермального барьера и микробным дисбиозом. АтД широко распространен, в том числе в детской популяции. В статье обсуждены патогенетические основы заболевания: неполноценность кожного барьера, иммунологические причины хронического воспаления, характеристика нормального кожного микробиома и его нарушения как на пораженной, так и на непораженной коже детей с АтД. Рассмотрены основные принципы системной терапии среднетяжелых и тяжелых форм заболевания. Обсуждены особенности таргетной терапии пациентов детского возраста со среднетяжелой и тяжелой формой АтД ингибитором IL 4/IL 13 — препаратом дупилумаб. Приводится обзор результатов исследований эффективности и безопасности дупилумаба.

1. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014; 70(2):338–351. doi: 10.1016/j.jaad.2013.10.010.

2. Odhiambo JA, Williams HC, Clayton TO, et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–1258.e23. doi: 10.1016/j.jaci.2009.10.009.

3. Ресурсы и деятельность медицинских организаций дер матовенерологического профиля. Заболеваемость инфекция ми, передаваемыми половым путем, заразными кожными болезнями и заболеваниями кожи за 2017–2018 годы. М.; 2019. С. 121–123.

4. Намазова-Баранова Л .С., Баранов А.А., Кубанова А.А. и др. Атопический дерматит у детей: современные клинические рекомендации по диагностике и терапии // Вопросы современной педиатрии. — 2016. — Т. 15. — № 3. — С. 279–293. doi: 10.15690/vsp.v15i3.1566.

5. Pols DHJ, Wartna JB , Moed H, et al. Atopic dermatitis, asthma and allergic rhinitis in general practice and the open population: a systematic review. Scand J Prim Health Care. 2016;34(2): 143–150. doi: 10.3109/02813432.2016.1160629.

6. Hill DA, Spergel JM . The Atopic March: Critical Evidence and Clinical Relevance. Ann Allergy Asthma Immunol. 2018;120(2): 131–137. doi: 10.1016/j.anai.2017.10.037.

7. Bieber T. Atopic De rmatitis. N Eng J Med. 2008;358(14): 1483–1494. doi: 10.1056/NEJMra074081.

8. Leung DY, Guttman-Y assky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–79. doi: 10.1016/j.jaci.2014.08.008.

9. Schmid-Grendelmeier P, Fluckiger S, Disch R, et al. IgE-me diated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol. 2005;115(5): 1068–1075. doi: 10.1016/j.jaci.2005.01.065.

10. Мурашкин Н.Н., Епиш ев Р.В., Фёдоров Д.В. и др. Синдром чувствительной кожи при атопическом дерматите у детей: особенности патогенеза и терапевтической тактики // Вопросы современной педиатрии. — 2019. — Т. 18. — № 4. — С. 285–293. doi: 10.15690/vsp.v18i4.2046.

11. Bunikowski R, Mielk e M, Skarabis H, et al. Prevalence and role of serum IgE antibodies to the Staphylococcus aureus-derived superantigens SEA and SEB in children with atopic dermatitis. J Allergy Clin Immunol. 1999;103(1 Pt 1):119–124. doi: 10.1016/s0091-6749(99)70535-x.

12. Paus R, Schmelz M, Biro T, Steinhoff M. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest. 2006;116(5):1174–1186. doi: 10.1172/JCI28553.

13. Artis D, Spits H. T he biology of innate lymphoid cells. Nature. 2015;517(7534):293–301. doi: 10.1038/nature14189.

14. Clark RA. Skin-Resi dent T Cells: The Ups and Downs of On Site Immunity. J Invest Dermatol. 2010;130(2):362–370. doi: 10.1038/jid.2009.247.

15. Szabo PA, Miron M, Farber DL. Location, location, location: Tissue resident memory T cells in mice and humans. Sci Immunol. 2019;4(34):eaas9673. doi: 10.1126/sciimmunol.aas9673.

16. Gollwitzer ES, Mars land BJ. Impact of Early-Life Exposures on Immune Maturation and Susceptibility to Disease. Trends Immunol. 2015;36(11):684–696. doi: 10.1016/j.it.2015.09.009.

17. Wynn TA. Type 2 cyt okines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282. doi: 10.1038/nri3831.

18. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443.

19. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132(2):259–272. doi: 10.1016/j.cell.2007.12.030.

20. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10(4):225–235. doi: 10.1038/nri2735.

21. Licari A, Castagnol i R, Marseglia A, et al. Dupilumab to Treat Type 2 Inflammatory Diseases in Children and Adolescents. Paediatric Drugs. 2020;22(3):295–310. doi: 10.1007/s40272-020-00387-2.

22. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701–738. doi: 10.1146/annurev.immunol.17.1.701.

23. Chiaramonte MG, Men tink-Kane M, Jacobson BA, et al. Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med. 2003;197(6):687–701. doi: 10.1084/jem.20020903.

24. Wood N, Whitters MJ , Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197(6):703–709. doi: 10.1084/jem.20020906.

25. Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии // Медицинский Алфавит. Дерматология. — 2019. — Т. 1. — № 7(382). — С. 29–32. doi: 10.33667/2078-5631-2019-1-7(382)-29-32.

26. Tanaka Y, Hamano S, Gotoh K, et al. T helper type 2 differentiation and intracellular trafficking of the interleukin 4 receptor-alpha subunit controlled by the Rac activator Dock2. Nat Immunol. 2007;8(10):1067–1075. doi: 10.1038/ni1506.

27. Noval Rivas M, Burt on OT, Wise P, et al. Regulatory T cell reprogramming toward a Th2-cell-like lineage impairs oral tolerance and promotes food allergy. Immunity. 2015;42(3):512–523. doi: 10.1016/j.immuni.2015.02.004.

28. Hershey GK, Friedri ch MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 1997;337(24):1720–1725. doi: 10.1056/NEJM199712113372403.

29. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354. doi: 10.1016/j.jaci.2012.07.012.

30. Honzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and -Defensins in Filaggrin-Deficient Skin Equivalents. J Invest Dermatol. 2016;136(3):631–639. doi: 10.1016/j.jid.2015.11.007.

31. Huang YJ, Marsland BJ, Bunyavanich S. et al. The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017; 139(4):1099–1110. doi: 10.1016/j.jaci.2017.02.007.

32. Мурашкин Н.Н., Материкин А.И., Опрятин Л.А. и др. Особенности микробиома кожи у детей с атопическим дерматитом и новые возможности для патогенетической терапии // Педиатрическая фармакология. — 2019. — Т. 16. — № 5. — С. 304–309. doi: 10.15690/pf.v16i5.2060.

33. Yosipovitch G, Papo iu ADP. What causes itch in atopic dermatitis? Curr Allergy Asthma Reps. 2008;8(4):306–311. doi: 10.1007/s11882-008-0049-z.

34. Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell. 2017;171(1):217–228.e13. doi: 10.1016/j.cell.2017.08.006.

35. Czarnowicki T, He H , Krueger JG, Guttman-Yassky E. Atopic derma titis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. doi: 10.1016/j.jaci.2018.10.032.

36. Lowe AJ, Leung DY M, Tang MLK, et al. The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol. 2018;120(2):145–151. doi: 10.1016/j.anai.2017.11.023.

37. Brunner PM, Suarez- Farinas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep. 2017;7(1):8701. doi: 10.1038/s41598-017-09207-z.

38. Ungar B, Garcet S, Gonzalez J, et al. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. J Investe Dermatol. 2017;137(3):603–613. doi: 10.1016/j.jid.2016.09.037.

39. Thibodeaux Q, Smith MP, Ly K, et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129–2139. doi: 10.1080/21645515.2019.1582403.

40. Del Rosso JQ. Monoc lonal antibody therapies for atopic dermatitis: where are we now in the spectrum of disease mana gement? J Clin Aesthet Dermatol. 2019;12(2):39–41.

41. Wang L-H, Xue Y, Mu rphy A, Stevens S. Humanized IL-4 and IL-4R alpha animals. Patent. Publication Number WO/2015/171861. Publication Date 12.11.2015. International Application No. PCT/ US2015/029638. International Filing Date 07.05.2015. US.

42. Kostic A, Kelly L, Liu X, Classon BJ. Methods for treating eosinophilic esophagitis by administering an IL-4r inhibitor. Patent. Publication Number WO/2015/006571. Publication Date 15.01.2015. International Application No. PCT/US2014/046170. International Filing Date 10.07.2014. US.

43. Simpson EL, Paller AS, Siegfried EC, et al Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020;156(1):44–56. doi: 10.1001/jamadermatol.2019.3336.

44. de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebocontrolled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156.

45. Regeneron Pharmaceuticals. Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants 6 to < 12 Years With Severe Atopic Dermatitis (AD). ClinicalTrials. gov. August 13, 2020. Available online: https://clinicaltrials.gov/ct2/show/study/NCT03345914. Accessed on September 12, 2020.

46. Callewaert C, Nakat suji T, Knight R, et al. IL-4R Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. J Invest Dermatol. 2020;140(1):191–202.e7. doi: 10.1016/j.jid.2019.05.024.

47. Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23–31. doi: 10.1159/000247298.

48. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96–102. doi: 10.1111/j.1365-2133.2004.05696.x.

49. Waters A, Sandhu D, Beattie P, et al. Severity stratification of Children’s Dermatology Life Quality Index (CDLQI) scores. Br J Dermatol. 2010;163(Suppl 1):121.

50. Lewis-Jones MS, Fin lay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144(1):104–110. doi: 10.1046/j.1365-2133.2001.03960.x.

51. Basra MKA, Sue-Ho R , Finlay AY. The Family Dermatology Life Quality Index: measuring the secondary impact of skin disease. Br J Dermatol. 2007;156(3):528–538. doi: 10.1111/j.1365-2133.2006.07617.x.

52. Lee JY, Kim M, Yang H-K, et al. Reliability and validity of the Atopic Dermatitis Symptom Score (ADSS). Pediatr Allergy Immunol. 2018;29(3):290–295. doi: 10.1111/pai.12865.

53. Cella D, Yount S, R othrock N, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(Suppl 1):S3–S11. doi: 10.1097/01.mlr.0000258615.

54. Posner K, Brown GK, Stanley B, et al. The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266–1277. doi: 10.1176/appi.ajp.2011.10111.

55. Matsunaga K, Katoh N, Fujieda S, et al. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2): 187–196. doi: 10.1016/j.alit.2020.01.002.

56. Мурашкин Н.Н., Материкин А.И., Амбарчян Э.Т., Епишев Р.В. Современные представления о патогенезе и принципах наружной терапии атопического дерматита у детей // Вопросы современной педиатрии. — 2016. — Т. 15. — № 6. — С. 584–589. doi: 1010.15690/vsp.v15i6.1655.

57. Coondoo A, Phiske M , Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4): 416–425. doi: 10.4103/2229-5178.142483.

58. Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther. 2016;7(1):1–23. doi: 10.1007/s13555-016-0170-1.

59. Patrizi A, Raone B, Ravaioli GM. Management of atopic derma titis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol. 2015;8:511–520. doi: 10.2147/ccid.s87987.

60. Ivert LU, Wahlgren CF, Ivert L, et al. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99(4):375–378. doi: 10.2340/00015555-3121.

61. Wenzel S, Ford L, P earlman D, et al., Dupilumab in per sistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368(26):2455–2466. doi: 10.1056/NEJMoa1304048.

62. Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA. 2016; 315(5):469–479. doi: 10.1001/jama.2015.19330.

63. Ou Z, Chen C, Chen A, et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a metaanalysis. Int Immunopharmacol. 2018;54:303–310. doi: 10.1016/j.intimp.2017.11.031.

64. Thomson J, Wernham A, Williams HC. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. Br J Dermatol. 2018;178(4):897–902. doi: 10.1111/bjd.16317.